Angiotensin II antagonists for hypertension: Are there differences in efficacy?

Show simple item record Conlin, P. R. Spence, J. D. Williams, B. Ribeiro, A. B. Saito, I Benedict, C. Bunt, AMG 2016-01-24T12:31:03Z 2016-01-24T12:31:03Z 2000-04-01
dc.identifier.citation American Journal of Hypertension. New York: Elsevier B.V., v. 13, n. 4, p. 418-426, 2000.
dc.identifier.issn 0895-7061
dc.description.abstract We compared the antihypertensive efficacy of available drugs in the new angiotensin-II-antagonist (AIIA) class. the antihypertensive efficacy of losartan, valsartan, irbesartan, and candesartan was evaluated from randomized controlled trials (RCT) by performing a metaanalysis of 43 published RCT. These trials involved AIIA compared with placebo, other antihypertensive classes, and direct comparisons between AIIA. A weighted-average for diastolic and systolic blood pressure reduction with AIIA monotherapy, dose titration, and with addition of low-dose hydrochlorothiazide (HCTZ) were calculated. Weighted-average responder rates were also determined. the metaanalysis assessed a total of 11,281 patients. the absolute weighted-average reductions in diastolic (8.2 to 8.9 mm Hg) and systolic (10.4 to 11.8 mm Hg) blood pressure reductions (not placebo-corrected) for AIIA monotherapy were comparable for all AIIA. Responder rates for AIIA monotherapy were 48% to 55%. Dose titration resulted in slightly greater blood pressure reduction and an increase in responder rates to 53% to 63%. AIIA/hydrochlorothiazide combinations produced substantially greater reduction in systolic (16.1 to 20.6 mm Hg) and diastolic (9.9 to 13.6 mm Hg) blood pressure reductions than AIIA monotherapy and responder rates for AIIA/HCTZ combinations were 56% to 70%. This comprehensive analysis shows comparable antihypertensive efficacy within the AIIA class, a near-flat AIIA-dose response when titrating from starting to maximum recommended dose, and substantial potentiation of the antihypertensive effect with addition of HCTZ. (C) 2000 American Journal of Hypertension, Ltd. en
dc.format.extent 418-426
dc.language.iso eng
dc.publisher Elsevier B.V.
dc.relation.ispartof American Journal of Hypertension
dc.rights Acesso restrito
dc.subject hypertension en
dc.subject randomized controlled trials en
dc.subject efficacy en
dc.subject review en
dc.subject angiotensin-II-antagonists en
dc.title Angiotensin II antagonists for hypertension: Are there differences in efficacy? en
dc.type Artigo
dc.contributor.institution Brigham & Womens Hosp
dc.contributor.institution Harvard Univ
dc.contributor.institution Univ Western Ontario
dc.contributor.institution Univ Leicester
dc.contributor.institution Universidade Federal de São Paulo (UNIFESP)
dc.contributor.institution Keio Univ
dc.contributor.institution Univ Texas
dc.contributor.institution Merck & Co Inc
dc.description.affiliation Brigham & Womens Hosp, Endocrinol Hypertens, Boston, MA 02115 USA
dc.description.affiliation Harvard Univ, Sch Med, Boston, MA 02115 USA
dc.description.affiliation Univ Western Ontario, Siebens Drake Robarts Res Inst, London, ON, Canada
dc.description.affiliation Univ Leicester, Inst Cardiovasc Res, Leicester, Leics, England
dc.description.affiliation UNIFESP, EPM, Div Nephrol, São Paulo, Brazil
dc.description.affiliation Keio Univ, Ctr Hlth, Tokyo, Japan
dc.description.affiliation Univ Texas, Sch Med, Houston, TX USA
dc.description.affiliation Merck & Co Inc, Whitehouse Stn, NJ USA
dc.description.affiliationUnifesp UNIFESP, EPM, Div Nephrol, São Paulo, Brazil
dc.identifier.doi 10.1016/S0895-7061(99)00237-X
dc.description.source Web of Science
dc.identifier.wos WOS:000086954400016


File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record




My Account